Abstract:Cancer and cardiovascular disease make up nearly half of all deaths in the United States. Despite knowing a great deal about each of these diseases individually, surprisingly little is known about how these diseases interact within patients or the common dysregulated genes and pathways that these diseases share. These diseases are known to share numerous risk factors and emerging epidemiologic data suggests that the presence of coronary artery disease (CAD) increases the risk of developing cancer. In addition, studies like the CANTOS trial have shown that targeting mutually detrimental pathways could yield benefit for both diseases. To understand the relationship of cancer and CAD, we tested two hypotheses, 1) the similarities between cancer and CAD are explained, in part, by shared genetic factors and 2) these diseases share dysregulated processes/pathogenic drivers and that targeting these processes could result in mutual clinical benefit. To test these hypotheses, we assessed the genetic correlation of CAD and each cancer subtype in the UK biobank. This identified a surprising genetic overlap between prostate cancer and CAD. However, the other cancers lacked significant genetic correlation with CAD, suggesting that common genetic factors were unlikely to be mediating their interaction. To identify common pathogenic drivers, we used transcriptomic data that had been correlated with either cancer survival or CAD disease severity/outcomes to generate transcriptional risk profiles for each disease. We then intersected these data to identify mutually detrimental processes, which included several known pathways including inflammation and hypoxia but also numerous novel pathways. Interestingly, we found that many cancers were indistinguishable from CAD based on their transcriptomic risk profile. Next, we used the drug prediction algorithm, OCTAD, to identify novel drug targets for each disease state and then validated our predictions using a pharmacovigilance approach with EMR data. Taken together, our study suggests that the interaction of cancer and CAD is primarily driven by shared pathogenic drivers rather than shared genetic predisposition and that targeting these processes may allow for mutual clinical benefit.

Shared Risk Factors in Cardiovascular Disease and Cancer

Cardiovascular disease and cancer: shared risk factors and mechanisms

Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients

Common risk factors for heart failure and cancer

Cancer as a Risk Factor for Cardiovascular Disease

Abstract 15727: Cancer and Atherosclerosis Share Numerous Pathogenic Drivers Representing Novel Translational Targets for Mutual Benefit

Identifying Shared Transcriptional Risk Patterns Between Atherosclerosis and Cancer.

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

Social Risk Factors That Increase Cardiovascular and Breast Cancer Risk

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Evolving data on cardiovascular complications in cancer

Interconnected Clinical and Social Risk Factors in Breast Cancer and Heart Failure

From Bench to Bedside—Part 1

Shared and Reciprocal Mechanisms Between Heart Failure and Cancer - An Emerging Concept of Heart-Cancer Axis

Cardiovascular health of patients with cancer: Challenges abound

Cardiovascular disease and lung cancer

Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis

Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES-Continuous Study

Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer

Association Between Obesity and Risk of Total and Obesity-Related Cancer in People With Incident Cardiovascular Disease